HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?

Similar documents
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Ian T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia

3D Printing & Echocardiography

Transcatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes

Percutaneous Mitral Valve Repair

Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know

ICE: Echo Core Lab-CRF

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR

Aortic Stenosis and Perioperative Risk With Non-cardiac Surgery

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

Percutaneous Therapy for Calcific Mitral Valve Disease

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Federico M Asch MD, FASE MedStar Heart and Vascular Institute Georgetown University Washington, DC

Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system

3D Printing & Echocardiography

How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min

Transcatheter Valve Replacement: Current State in 2017

TAVR: Echo Measurements Pre, Post And Intra Procedure

Prosthetic valve dysfunction: stenosis or regurgitation

Echocardiographic Evaluation of Aortic Valve Prosthesis

TAVR IN INTERMEDIATE-RISK PATIENTS

25 different brand names >44 different models Sizes mm

PROSTHETIC VALVE BOARD REVIEW

Nouvelles indications/ Nouvelles valves

Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis?

VARC-2 and MVRC definitions Ioannis Iakovou, MD, PhD

My Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.

Aortic Valve Stenosis and TAVR: Putting it all together.

1-YEAR OUTCOMES FROM JOHN WEBB, MD

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Prognostic Impact of FMR

Low Gradient Severe AS: Who Qualifies for TAVR? Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor

TAVR Cases. Disclosures 2/17/2018. February 17, :15 3:30 PM 15 min

Mixed aortic valve disease

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Structural Heart Disease: Setting the Stage for Success

Paravalvular Regurgitation is a Risk Factor Following TAVI

Culprit vs Multivalve Transcatheter Intervention

30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study

One-year outcomes with the transcatheter LOTUS Edge Aortic Valve System

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Stress Testing in Valvular Disease

Adult Echocardiography Examination Content Outline

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

What are the best diagnostic tools to quantify aortic regurgitation?

Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

Διαδερμική θεραπεία των παραβαλβιδικών διαφυγών Σ.Ράμμος

Michigan Society of Echocardiography 30 th Year Jubilee

30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators

Outline. EuroScore II. Society of Thoracic Surgeons Score. EuroScore II

DOPPLER HEMODYNAMICS (1) QUANTIFICATION OF PRESSURE GRADIENTS and INTRACARDIAC PRESSURES

Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience

In Process, Unpublished STS/ACC TVT Registry Manuscripts

PVL Assessment. Is paravalvular regurgitation after TAVR still an important consideration in 2018?

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Transcatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President

Management of Difficult Aortic Root, Old and New solutions

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

Echo Assessment Pre-TAVI

Echocardiographic Evaluation of Aortic Valve Prosthesis

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

TAVR SPRING 2017 The evolution of TAVR

CoreValve in a Degenerative Surgical Valve

Successful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder

Disclosures Rebecca T. Hahn, MD, FASE

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Professors Carpentier and McGoon Mechanism, resulting from the disease Severity of regurgitation, resulting from the mechanism Echo

PORTICO CE TRIAL ASSESSMENT OF THE ST. JUDE MEDICAL PORTICO TRANSCATHETER AORTIC VALVE IMPLANT AND THE TRANSFEMORAL DELIVERY SYSTEM

8/31/2016. Mitraclip in Matthew Johnson, MD

ECHOCARDIOGRAPHY DATA REPORT FORM

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Indication, Timing, Assessment and Update on TAVI

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

DISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.

Update on Transcatheter Mitral Valve Repair and Replacment

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

TAVR in 2020: What is Next!!!!

Valvular Imaging Optimizing Data Acquisition and Interpretation

Patient/prosthesis mismatch: how to evaluate and when to act?

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Section 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient

Vinod H. Thourani, MD, FACC, FACS

MitraClip World Wide Commercial Experience

Asymptomatic Valvular Disease:

Hemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics

Aortic Stenosis: Spectrum of Disease, Low Flow/Low Gradient and Variants

Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison

MITRAL REGURGITATION ECHO PARAMETERS TOOL

Introducing the COAPT Trial

Transcatheter heart valve thrombosis

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010

Transcription:

HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado TVT Registry Steering Committee Susan Fitzgerald, RN, MSN Associate Director, Registry Development Disclosures Dr. Carroll has a relationship with: AGA Medical/ST Jude Medical Corporation Evalve/Abbott Structural Heart Disease Phillips HealthCare Steering Committee RESPECT Susan Fitzgerald has no disclosures Why Are Echo Measurements So Important? Registry Disease Diagnostic Tools CathPCI Coronary artery disease Stress test or diagnostic cath ICD Arrhythmias TVT Heart valve disease Electrophysiology studies Echocardiogram 1

Assessment and Diagnosis of Heart Valve Disease Gold standard - echocardiography Echo variables are required to assess heart valve function for all transcatheter valve procedures Baseline Post procedure Follow-up (30 day and 1 year) Cardiac catheterization does not capture many variables to assess function of heart valve Diagnosis of Heart Valve Disease Symptoms New York Heart Association (NYHA) classification Valve anatomy Bicuspid vs tricuspid aortic valve Valve area Effective orifice area (EOA) or effective regurgitant orifice area (EROA) in cm2 Diagnosis of Heart Valve Disease Valve hemodynamics Angiographic grade (1+ - 3+) Gradient Velocity Hemodynamic consequences of valve disease Ejection fraction 2

What are the Echo Guidelines/Standards? Not aligned ASSESSMENT OF MITRAL REGURGITATION AHA/ACCF Classification of Mitral Regurgitation (MR) Anatomy (e.g. prolapse) Symptoms Severity (mild-severe) Hemodynamics Angiographic grade (1+ -3+) Effective orifice area (EOA) or effective regurgitantorifice area (EROA) in cm2 Consequences (atrial or ventricular enlargement, ejection fraction) 3

Classification of MR What is the Difference? Type ASE Any AHA/ACCF Primary (DMR) and secondary (FMR) classified separately Classification Mild-moderate-severe Grade A - D Symptoms Valve anatomy Valve hemodynamics (e.g. doppler study of jets and quantitative parameters (EROA) Hemodynamic consequences (e.g. LA and LV size) (normal or abnormal) (more descriptive - valve prolapse, flail thickening of leaflets) Classification of MR Different EROA Between Standards ASE AHA/ACCF Grade EROA (cm 2 ) Grade EROA (cm 2 ) Mild < 0.20 A < 0.40 Moderate (mild-mod) 0.20-0.29 B < 0.40 (mod-severe) 0.30-0.39 C >=0.40 Severe >=0.40 D >=0.40 ASSESSMENT OF AORTIC STENOSIS 4

AHA/ACCF Staging of Aortic Stenosis (Stage A-D) Symptoms Valve anatomy Bicuspid Calcification Valve area Valve hemodynamics Gradient Velocity Hemodynamic consequences (left ventricular dysfunction, hypertrophy and reduced ejection fraction) Morphology of Aortic Stenosis Valve Area (Mitral or Aortic) VARC endpoint - device success Key measure in regulatory definition of device success 5

TAVR - Device Success VARC 1 Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system. Correct position of the device in the proper anatomical location; Only one valve implanted in the proper anatomical location. Intended performance of the prosthetic heart valve (aortic valve area >1.2 cm2 and mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s, without moderate or severe prosthetic valve AR). TVT Registry Registry Report Metric Correct positioning of a single prosthetic heart valve in the proper anatomical location (Device Implanted Successfully) Mean AV gradient <20 (post implant or post-procedure) and post procedure aorticinsufficiency = none; trace/trivial or mild. Conversion to open heart surgery = no 1 Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials (JACC, 2011, vol 57, No 3) Paravalvular Leaks Classifying Regurgitation Coding Challenges No gold standard American Society for Echo (ASE) and AHA/ACCF Guidelines not aligned Echo reports not consistent or missing key variables Current registry specs: Up-code to highest value Includes a category for trace which isn t described in current classifications Not aligned with AHA/ACCF standards 6

QUESTIONS? 7